Literature DB >> 12756292

Suppression of macrophage inflammatory responses by PPARs.

Peter Henson1.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12756292      PMCID： PMC164439          DOI： 10.1073/pnas.1232410100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  13 in total

Review 1.  The phosphatidylserine receptor: a crucial molecular switch?

Authors:  P M Henson; D L Bratton; V A Fadok
Journal:  Nat Rev Mol Cell Biol       Date:  2001-08       Impact factor: 94.444

Review 2.  Alternative activation of macrophages.

Authors:  Siamon Gordon
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

Review 3.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.

Authors:  Alberto Mantovani; Silvano Sozzani; Massimo Locati; Paola Allavena; Antonio Sica
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

4.  Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo.

Authors:  R Thieringer; J E Fenyk-Melody; C B Le Grand; B A Shelton; P A Detmers; E P Somers; L Carbin; D E Moller; S D Wright; J Berger
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

5.  PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation.

Authors:  A Chawla; Y Barak; L Nagy; D Liao; P Tontonoz; R M Evans
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

6.  The role of PPAR-gamma in macrophage differentiation and cholesterol uptake.

Authors:  K J Moore; E D Rosen; M L Fitzgerald; F Randow; L P Andersson; D Altshuler; D S Milstone; R M Mortensen; B M Spiegelman; M W Freeman
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

7.  Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages.

Authors:  Geert Raes; Patrick De Baetselier; Wim Noël; Alain Beschin; Frank Brombacher; Gholamreza Hassanzadeh Gh
Journal:  J Leukoc Biol       Date:  2002-04       Impact factor: 4.962

8.  PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

Authors:  C Jiang; A T Ting; B Seed
Journal:  Nature       Date:  1998-01-01       Impact factor: 49.962

Review 9.  Recent advances in peroxisome proliferator-activated receptor science.

Authors:  Barry G Shearer; William J Hoekstra
Journal:  Curr Med Chem       Date:  2003-02       Impact factor: 4.530

Review 10.  Peroxisome proliferator-activated receptor-gamma in macrophage lipid homeostasis.

Authors:  Chih-Hao Lee; Ronald M Evans
Journal:  Trends Endocrinol Metab       Date:  2002-10       Impact factor: 12.015
View more
  13 in total

1.  Dynamics of lung macrophage activation in response to helminth infection.

Authors:  Mark C Siracusa; Joshua J Reece; Joseph F Urban; Alan L Scott
Journal:  J Leukoc Biol       Date:  2008-08-21       Impact factor: 4.962

2.  Autoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency.

Authors:  Tamás Roszer; María P Menéndez-Gutiérrez; Martina I Lefterova; Daniel Alameda; Vanessa Núñez; Mitchell A Lazar; Thierry Fischer; Mercedes Ricote
Journal:  J Immunol       Date:  2010-12-06       Impact factor: 5.422

3.  Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.

Authors:  Minghua Wu; Denisa S Melichian; Eric Chang; Matthew Warner-Blankenship; Asish K Ghosh; John Varga
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 4.  Targeting host factors: a novel rationale for the management of hepatitis C virus.

Authors:  Mahmoud Aboelneen Khattab
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

5.  Effect of rosuvastatin on OX40L and PPAR-γ expression in human umbilical vein endothelial cells and atherosclerotic cerebral infarction patients.

Authors:  Jing-Yu Zhang; Bin Liu; Ya-Nan Wang; Wei-Na Zhang; Feng-Jun Wang
Journal:  J Mol Neurosci       Date:  2013-10-27       Impact factor: 3.444

6.  Preclinical studies of a specific PPARγ modulator in the control of skin inflammation.

Authors:  Arianna Mastrofrancesco; Daniela Kovacs; Massimiliano Sarra; Emanuela Bastonini; Giorgia Cardinali; Nicaela Aspite; Emanuela Camera; Philippe Chavatte; Pierre Desreumaux; Giovanni Monteleone; Mauro Picardo
Journal:  J Invest Dermatol       Date:  2013-10-28       Impact factor: 8.551

7.  Brd4 modulates diet-induced obesity via PPARγ-dependent Gdf3 expression in adipose tissue macrophages.

Authors:  Xiangming Hu; Xingchen Dong; Guo Li; Yanheng Chen; Jinjing Chen; Xiaoxin He; Hao Sun; Dong-Hyun Kim; Jongsook Kim Kemper; Lin-Feng Chen
Journal:  JCI Insight       Date:  2021-04-08

Review 8.  New treatments for chronic hepatitis C.

Authors:  Jae Young Jang; Raymond T Chung
Journal:  Korean J Hepatol       Date:  2010-09

9.  Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance.

Authors:  Francesco Negro
Journal:  PPAR Res       Date:  2009-01-06       Impact factor: 4.964

10.  Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination.

Authors:  Antoinette Defaux; Marie-Gabrielle Zurich; Olivier Braissant; Paul Honegger; Florianne Monnet-Tschudi
Journal:  J Neuroinflammation       Date:  2009-05-07       Impact factor: 8.322
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.